(NYSE: DNA) Ginkgo Bioworks Holdings's forecast annual revenue growth rate of 2.8% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Ginkgo Bioworks Holdings's revenue in 2025 is $237,417,000.On average, 1 Wall Street analysts forecast DNA's revenue for 2025 to be $10,594,269,737, with the lowest DNA revenue forecast at $10,594,269,737, and the highest DNA revenue forecast at $10,594,269,737. On average, 1 Wall Street analysts forecast DNA's revenue for 2026 to be $11,413,716,015, with the lowest DNA revenue forecast at $11,413,716,015, and the highest DNA revenue forecast at $11,413,716,015.
In 2027, DNA is forecast to generate $15,668,866,409 in revenue, with the lowest revenue forecast at $15,668,866,409 and the highest revenue forecast at $15,668,866,409.